The global healthcare industry, often viewed as a beacon of human progress and life-saving innovation, is grappling with a profound internal contradiction. While pharmaceutical giants and biotechnology firms have increasingly championed ambitious environmental, social, and governance (ESG) goals, the sector’s actual carbon footprint continues to expand. As the industry scales up production to meet the demands of an aging global population and emerging health threats, it finds itself responsible for approximately 4.4% of total global greenhouse gas emissions—a figure that is moving in the wrong direction despite high-profile pledges.
The Magnitude of the Challenge: Main Facts
The healthcare supply chain is the primary engine of the industry’s environmental impact, accounting for roughly 71% of its total emissions. Within this ecosystem, the production of medicines—ranging from Active Pharmaceutical Ingredient (API) synthesis to large-scale manufacturing—is responsible for between 20% and 55% of the total carbon footprint.
The core of the issue lies in the resource-intensive nature of chemical synthesis. Traditional pharmaceutical manufacturing is notoriously inefficient; it is estimated that producing just one kilogram of an active drug can generate between 25 and 100 kilograms of chemical waste. Furthermore, solvents, which are essential to these processes, account for 80% to 90% of the total mass involved in drug production. This creates a high Process Mass Intensity (PMI), with median ranges between 168 and 308—figures that dwarf those found in other chemical manufacturing sectors.
Beyond carbon, the environmental impact extends to water and soil contamination. Pharmaceutical residues resulting from patient excretion, manufacturing plant discharge, and improper disposal of unused medication are increasingly appearing in local ecosystems. While current levels in drinking water are deemed a low immediate risk to human health, scientists are sounding the alarm on the long-term ecological consequences, particularly regarding the role of antibiotic residues in manufacturing effluent, which may be fueling the global crisis of antibiotic-resistant "superbugs."
A Chronology of Climate Commitments and Setbacks
The trajectory of the pharmaceutical industry’s environmental engagement over the last five years reveals a disconnect between intent and outcome:
- 2020–2021: The industry’s carbon footprint saw a significant spike, with total output from public companies rising by 15%, jumping from 197 million metric tons of CO2 equivalent (tCO2e) to 227 million.
- 2022: Data indicated that the healthcare sector’s share of global emissions rose to 5%, up from 3.9% the previous year, highlighting that growth in production was significantly outpacing efficiency gains.
- 2024: A pivotal year for reporting, where sector alignment with the 1.5°C climate trajectory was measured at 30%, showing a growing awareness but limited progress in implementation.
- 2025: The My Green Lab 2025 Carbon Impact Report indicated that alignment with the 1.5°C goal improved to 52%. However, the same period saw a 2% increase in absolute emissions, demonstrating that even as companies align their goals with science-based targets, their physical operations continue to generate more carbon.
- 2026: Leading firms, such as AstraZeneca, began reporting on the maturation of their sustainability roadmaps, with specific targets for operational emissions reductions, even as their Scope 3 (supply chain) emissions continued to climb.
Supporting Data: The "Scope 3" Barrier
The industry categorizes its emissions under the GHG Protocol. While Scopes 1 and 2 (direct emissions and purchased energy) have seen reductions among the top 25 global players, Scope 3 emissions remain the "Achilles’ heel" of the sector. Scope 3 covers everything from raw material sourcing and logistics to the disposal of final products, and it accounts for a staggering 82% of the industry’s total carbon footprint.
The difficulty in curbing these emissions is rooted in their origin: they occur outside the direct control of the pharmaceutical manufacturer. For example, Eli Lilly saw its Scope 3 emissions rise from approximately 2.99 million metric tons in 2021 to 5.14 million in 2023. Similarly, AstraZeneca, while making progress on operational efficiency, saw its absolute Scope 3 emissions grow by 24% from its 2019 baseline.
These figures illustrate a "scale-up paradox." As companies like Novo Nordisk experience rapid growth—evidenced by a 19% increase in emissions between 2024 and 2025 due to new site acquisitions—the carbon intensity of their infrastructure often grows faster than their ability to implement renewable energy or green chemistry processes.
Official Responses and Corporate Strategy
Major industry players are responding to these pressures with a blend of technological innovation and supply-chain management.
AstraZeneca has emerged as a leader in transparency, reporting that it is on track to achieve a 98% reduction in operational emissions by 2026. Their strategy includes a 23% reduction in water use and a 13% reduction in waste production as of 2025. Meanwhile, Sanofi has taken an aggressive stance on neutrality, aiming for carbon neutrality by 2030. As of 2024, they had already realized a 47% reduction in emissions against their 2019 baseline and are now focusing on implementing strict monitoring systems to control the release of pharmaceutical residues into the environment across all manufacturing sites.
However, the industry’s reliance on outsourced manufacturing and complex global supply chains complicates these efforts. Many companies are now pivoting toward:
- Supplier Incentivization: Requiring key manufacturing partners to adopt sustainability targets and transition to renewable energy as a condition of the contract.
- Logistical Overhauls: Moving away from energy-intensive air freight toward sea or road transport to reduce the carbon impact of moving raw materials and finished drugs.
- Green Chemistry: Investing in solvent recovery systems and catalytic processes to lower the PMI of drug synthesis.
Implications for the Future of Global Health
The implications of the pharmaceutical sector’s emissions are twofold: immediate and long-term. In the immediate term, the failure to curb emissions threatens the industry’s "social license to operate." As public scrutiny of ESG performance intensifies, pharmaceutical companies face potential regulatory pressure, carbon taxes, and investor divestment if they cannot demonstrate tangible progress in reducing their total carbon footprint.
In the long term, the environmental impact of drug production threatens the very health systems the industry serves. The release of pharmaceutical residues—particularly antibiotics—into the environment is a significant contributor to the global rise of antibiotic resistance. If the manufacturing of medicines inadvertently fosters the development of superbugs, the industry will have created a self-perpetuating cycle of health crises.
Furthermore, the industry is caught in a dilemma of accessibility versus sustainability. As the global population grows and demands affordable, life-saving medicines, the pressure to produce more volume often conflicts with the need to produce more sustainably. To reconcile this, the sector must move beyond voluntary, fragmented initiatives toward a standardized, industry-wide adoption of green manufacturing protocols.
The My Green Lab reports and the rising Scope 3 figures serve as a sobering reminder that voluntary commitments are only as effective as the systemic changes they trigger. For the pharmaceutical industry to truly align with a 1.5°C future, it must move beyond the low-hanging fruit of operational energy efficiency and tackle the fundamental architecture of its supply chain. Without a radical transformation in how drugs are synthesized, sourced, and shipped, the industry’s environmental footprint will continue to undermine its core mission: to improve the health and well-being of the global population.
About the Author
